With the advent of decentralized manufacturing and other tools to lower the cost of goods, new business models that empower centers of excellence to become manufacturers will emerge. The broader business question is which indications are best suited for not-for-profit institutions and which are best suited for biotech and pharma. And right now that is a pretty thorny question.
read full article ›